Vorinostat
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100940

CAS#: 149647-78-9

Description: Vorinostat, also known as suberanilohydroxamic acid, MK-0683 and SAHA, is a potent and selective inhibitor of histone deacetylases (HDACs). Vorinostat has been shown to bind to the active site of histone deacetylases and act as a chelator for Zinc ions also found in the active site of histone deacetylases. Vorinostat's inhibition of histone deacetylases results in the accumulation of acetylated histones and acetylated proteins, including transcription factors crucial for the expression of genes needed to induce cell differentiation. Vorinostat was approved for the treatment of cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after treatment with other medicines.


Price and Availability

Size
Price

1g
USD 110
50g
USD 2450
Size
Price

5g
USD 350
200g
USD 4950
Size
Price

10g
USD 650

Vorinostat, purity > 99%, is in stock. The same day shipping out after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide).


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 100940
Name: Vorinostat
CAS#: 149647-78-9
Chemical Formula: C14H20N2O3
Exact Mass: 264.14739
Molecular Weight: 264.3202
Elemental Analysis: C, 63.62; H, 7.63; N, 10.60; O, 18.16


Synonym: MK-0683, MK 0683, MK0683, SAHA, M344, CCRIS 8456, HSDB 7930, Vorinostat, suberoylanilide hydroxamic acid, Zolinza

IUPAC/Chemical Name: N1-hydroxy-N8-phenyloctanediamide

InChi Key: WAEXFXRVDQXREF-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)

SMILES Code: O=C(NO)CCCCCCC(NC1=CC=CC=C1)=O


Technical Data

Appearance:
White to off-white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

 
 
 
 
 


References

 1: Duvic M, Dimopoulos M. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. Cancer Treat Rev. 2016 Feb;43:58-66. doi: 10.1016/j.ctrv.2015.04.003. Epub 2015 Apr 9. Review. PubMed PMID: 26827693.

2: Afifi S, Michael A, Azimi M, Rodriguez M, Lendvai N, Landgren O. Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat. Pharmacotherapy. 2015 Dec;35(12):1173-88. doi: 10.1002/phar.1671. Review. PubMed PMID: 26684557.

3: Iwamoto M, Friedman EJ, Sandhu P, Agrawal NG, Rubin EH, Wagner JA. Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer Chemother Pharmacol. 2013 Sep;72(3):493-508. doi: 10.1007/s00280-013-2220-z. Epub 2013 Jul 3. Review. PubMed PMID: 23820962.

4: Lynch DR Jr, Washam JB, Newby LK. QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. Cardiol J. 2012;19(4):434-8. Review. PubMed PMID: 22825908.

5: Prebet T, Vey N. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs. 2011 Feb;20(2):287-95. doi: 10.1517/13543784.2011.542750. Epub 2010 Dec 31. Review. PubMed PMID: 21192773.

6: Richon VM. Targeting histone deacetylases: development of vorinostat for the treatment of cancer. Epigenomics. 2010 Jun;2(3):457-65. doi: 10.2217/epi.10.20. Review. PubMed PMID: 22121904.

7: Kavanaugh SM, White LA, Kolesar JM. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. Am J Health Syst Pharm. 2010 May 15;67(10):793-7. doi: 10.2146/ajhp090247. Review. Erratum in: Am J Health Syst Pharm. 2010 Jul 15;67(14):1136. Kavanaugh, Shannon A [corrected to Kavanaugh, Shannon M]. PubMed PMID: 20479100.

8: Zirlik K, Nashan D, Veelken H. [Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors]. Pharm Unserer Zeit. 2010 May;39(3):190-6. doi: 10.1002/pauz.201000365. Review. German. PubMed PMID: 20425773.

9: Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, Garcia-Vargas J, Sanz-Rodriguez C, Rizvi S. Vorinostat in solid and hematologic malignancies. J Hematol Oncol. 2009 Jul 27;2:31. doi: 10.1186/1756-8722-2-31. Review. PubMed PMID: 19635146; PubMed Central PMCID: PMC2731787.

10: Richon VM, Garcia-Vargas J, Hardwick JS. Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett. 2009 Aug 8;280(2):201-10. doi: 10.1016/j.canlet.2009.01.002. Epub 2009 Jan 31. Review. PubMed PMID: 19181442.

11: Heymann WR. Treatment of cutaneous T-cell lymphoma: focus on vorinostat. J Am Acad Dermatol. 2008 Oct;59(4):696-7. doi: 10.1016/j.jaad.2008.03.006. Review. PubMed PMID: 18793938.

12: Duvic M, Vu J. Vorinostat in cutaneous T-cell lymphoma. Drugs Today (Barc). 2007 Sep;43(9):585-99. Review. PubMed PMID: 17940636.

13: Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2007 Jul;16(7):1111-20. Review. PubMed PMID: 17594194.

14: Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007 Jan;25(1):84-90. Review. PubMed PMID: 17211407.